

Attorney Docket No: 1216-1-006/CIP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

NT(S):

Richard N. Kolesnick et al.

SERIAL NO:

10/727,358

EXAMINER:

Brian A. Whiteman

DATE FILED:

December 3, 2003

ART UNIT:

1635

FOR:

KINASE SUPPRESSOR OF RAS INACTIVATION FOR THERAPY OF

RAS MEDIATED TUMORIGENESIS

CERTIFICATE OF MAILING UNDER 37 CFR §1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on October 13, 2006.

Pamela De Marco (Name of depositor)

Signature and Date)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION_DISCLOSURE_STATEMENT

Sir:

In accordance with Applicant's and Applicant's representatives' Duty of Disclosure under 37 CFR § 1.56, and pursuant to 37 CFR §1.97, Applicant(s) submit herewith documentary information for consideration by the Examiner. Information herein cited is only set forth in fulfillment of Applicant's duty of candor in disclosing all information brought to his attention, and is not an admission that it can be used adversely. The publications forwarded herewith are listed on the enclosed Form PTO-1449. Applicant(s) request that the Examiner, upon reviewing the enclosed materials, initial the enclosed form and return a copy thereof in accordance with the instructions on the form.

Enclosed please find copies of References AA through DW listed on the attached Form PTO-1449. Since this Information Disclosure Statement is filed after mailing of the First Office Action, but prior to mailing of a Final Office Action or Notice of Allowance, a check in the amount of \$180.00 is included to cover the fee due pertinent to C.F.R. 37 §1.97(c). Please charge any additional fees, or credit any overpayments, to Deposit Account 11-1153.

10/17/2006 TTRAN1

00000014 10727358

01 FC:1806

180.00 OP

Christine E. Dietzel, Ph.D.

Respectfully submitted.

Agent for Applicants Registration No. 37,309

KLAUBER & JACKSON, LLC. 411 Hackensack Avenue Hackensack, New Jersey 07601 (201) 487-5800

Date: October 13, 2006

			Sheet 1 or 4
	Form PTO-1449 IRSY, 7.801 Department of Commerce Calent and Trademark Office	ATTORNEY DOCKET NO.	1216-1-006/CIP
(3	DCT 1 6 2006	SERIAL NO.	10/727,358
1/8	CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT	Richard N. Kolesnick, et al.
		FILING DATE	December 3, 2003
		GROUP	1635

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA	6,416,951	7/9/02	Schmidt et al.			
	АВ	6,500,615	12/31/02	Schmidt et. al.			
	AC	6,277,981	8/21/01	Tu et al.			
	AD	5, 591,721	1/7/97	Agrawal et al.			
	AE	2003/0109466	6/12/03	Monia et al.			
	AE	5,747,288	5/5/98	Rubin et al.			
	AG	5,700,675	12/23/97	Rubin et al.			
	АН	5,747,275	5/5/98	Rubin et al.			

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
ва	US03/16961	5/29/03	PCT			
вв	WO97/21820	6/19/97	Rubin et al.			

FXAM	INIED:
	IIVED.

DATE CONSIDERED:

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609;

Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 IRSY. 7.801 U.S. Department of Commerce Patent and Trademark Office	ATTORNEY DOCKET NO.	1216-1-006/CIP
	SERIAL NO.	10/727,358
LIST OF DOCUMENTARY INFORMATION	APPLICANT	Richard N. Kolesnick, et al.
CITED BY APPLICANT (Use several sheets if necessary)	FILING DATE	December 3, 2003
	GROUP	1635

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

CA	Agrawal, S., Temsamani, J. & Tang, J.Y. (1991) Proc. Natl. Acad Sci U.S.A. 88:7595-7599
СВ	Almoguera, C. et al (1988) Cell. 53:549-554
cc	Balaban, N. et al. (1996) Biochim Biophys Acta. 1314:147-156
CD Banerjee, D. (2001) Curr Opin Investig Drugs 2:574-580	
CE	Bennett et al. (1994) J. Immunol. 152:3530-3540
 CF	Bernhard, E.J. et al. (1998) Cancer Res. 58:1754-1761
CG	Bernhard, E.J. et al. (2000) Cancer Res. 60:6597-6600
СН	Bos, J. (1989) Cancer Res. 49: 4683-4689
CI	Brummelkamp, T.R. et al. (2002) Cancer Cell 2:243-247
CJ	Dean et al. (1994) J. Biol. Chem. 269:16446-16424
СК	Denouel-Galy, A. et al. (1998) Curr. Biol. 8:46-55
CL	Duff et al. (1995) J. Biol. Chem. 270:7161-7166
 СМ	Geary, R.S. et al. (1997) Anticancer Drug Des 12:383-393
CN	Genbank Accession No. U43585; ROD 1/30/96
со	Genbank Accession No. NM _013571; ROD 1/7/02
СР	Gokhale, P.C. et al. (1999) Antisense Nucleic Acid Dru Dev. 9:191-201
ca	Grant, M.L. et al. (1990) Oncogene 5:1159-1164

EXAMINER:	DATE CONSIDERED:
*EXAMINER: Initial if reference considered, whether or not citati Draw line through citation if not in conformance and not conside to applicant.	ion is in conformance with MPEP 609; red. Include copy of this form with next communication

Form PTO-1449 IRSY. 7.801 U.S. Department of Commerce	ATTORNEY DOCKET NO.	1216-1-006/CIP
Patent and Trademark Office	SERIAL NO.	10/727,358
LIST OF DOCUMENTARY INFORMATION	APPLICANT	Richard N. Kolesnick, et al.
CITED BY APPLICANT (Use several sheets if necessary)	FILING DATE	December 3, 2003
	GROUP	1635

CR	Gupta, A.K. et al. (2000) Radiat Res. 154:64-72	
cs	Gupta, A.K. et al. (2001) Cancer Ras 61:4278-4282	
СТ	Henry, S.P. et al. (1997) Anticancer Drug Des 12:395-408	
CU Ho et al. (1996) Nucl Acids Res 24:1901-1907		
cv	Ho et al. (1998) Nature Biotechnology 16:59-630	
cw	Jones, H. et al. (2001) Semin Radiat Oncol. 11:328-337	
сх	Kabanov, et al. (1990) FEBS Lett. 259:327	
CY	Kornfeld, K., Hom, D.B. & Horvitz, H.R. (1995) Cell 83:903-913	
CZ Kushner, D.M. and Silverman, R.H. (2000) Curr Oncol Rep 2:23-30		
DA	DA Laptev et al. (1994) Biochem. 33:11033-11039	
DB	Lozano, J. et al (2003) Cancer Research 63:4232-4238	
DC	Migley, R.S. and Kerr, D.J. (2002) Crit Rev Oncol Hematol. 44:109-120	
DD	Mishra et al. (1994) Life Sciences 317:977-982	
DE	Monia et al. (1992) J. Biol. Chem. 267:19954-19962	
DF	McKenna, W.G. (1990) Int J Radiat Oncol Biol Phys 18:849-859	
DG	McKenna, W.G. et al. (1990) Cancer Res 50:97-102	
DH	Nguyen, A. et al. (2002) Mol. Cell Biol. 22:3035-3045	
DI	Ogiso, Y. et al. (1994) Gene Ther 1:403-407	

EXAMINER:	DATE CONSIDERED:

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 4 of

Form PTO-1449 IRSY. 7.801 U.S. Department of Commerce Patent and Trademark Office	ATTORNEY DOCKET NO.	1216-1-006/CIP
	SERIAL NO.	10/727,358
LIST OF DOCUMENTARY INFORMATION	APPLICANT	Richard N. Kolesnick, et al.
CITED BY APPLICANT (Use several sheets if necessary)	FILING DATE	December 3, 2003
	GROUP	1635

DJ	Ohmachi, M. et al. (2002) Curr Biol 12:427-433
DK	Ojala et al (1997) Antisense Nucl Drug Dev. 7:31-38
DL	Sundaram, M. & Han, M. (1995) Cell 83:889-901
DM	Therrien, M. et al. (1995) Cell 83:879-888
DN	Wang et al. (1995) Proc. Natl. Acad. Sci. USA 92:3318-3322
DO	Xing, H., Kornfeld, K. & Muslin, A.J. (1997) Curr. Biol. 7:294-300
DP	Xing, H.R., Lozano, J. and Kolesnick, R. (2000) J. Biol. Chem. 275:17267-17280
DQ	Xing, H.R. and Kolesnick, R. (2001) J. Biol. Chem. 276: 9733-9741
DR	Xing, H.R. and Kolesnick, R. (2002) Proc. Amer. Assoc. Cancer Res. 43:720 (Abstract #3571)
DS	Xing, H.R. et al. (2003) Nature Med. 9:1266-1268 (Epub September 7, 2003)
DT	Xing, H.R. et al. (2003) Proc. Amer. Assoc. Cancer Res. 44(2):192 (Abstract #960)
DU	Yamagami et al. (1996) Blood 87:2878-2884
DV	Yao, B. et al. (1995) Nature 378:307-310
DW	Zhang, Y. et al. (1997) Cell 89:63-72
	DK DL DM DN DO DP DQ DR DS DT DU DV

EXAMINER:	DATE CONSIDERED:

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609;
Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.